Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria

For patients with advanced hepatocellular carcinoma (HCC), sorafenib is the only systemic treatment recommended by international guidelines. We recently reported that HCC patients with a low MoRAL (model to predict tumor recurrence after LDLT) score (≤ 314.8) have excellent treatment outcomes after...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Yuri, Lee, Jeong-Hoon, Lee, Dong Hyeon, Cho, Eun Ju, Yu, Su Jong, Yi, Nam-Joon, Lee, Kwang-Woong, Kim, Yoon Jun, Yoon, Jung-Hwan, Suh, Kyung-Suk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564586/
https://www.ncbi.nlm.nih.gov/pubmed/28548930
http://dx.doi.org/10.18632/oncotarget.17733

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564586/
https://www.ncbi.nlm.nih.gov/pubmed/28548930
http://dx.doi.org/10.18632/oncotarget.17733

Ejemplares similares